Abstract:

Objective To investigate the therapeutic effect of Jinlida granules on the liver injury of mice with type 1 diabetes mellitus and possible mechanisms. Methods The SD mouse model of type 1 diabetes mellitus was established by a single intraperitoneal injection of streptozotocin (STZ). The model rats were randomly divided into the model group (DM group), 0.75 g/kg, 1.5 g/kg, and 3.0 g/kg therapy groups. A normal control group (NC group) was established and there were 10 rats in every group. The fasting glucose (FBG), HbA1C, insulin, C-peptide, liver function indexes, hepatic fibrosis indexes, oxidative stress indexes, and inflammation indexes were detected and pathological changes of liver tissues were observed 8 weeks after the administration. Results Compared with the NC group, levels of FBG, liver enzyme, hepatic fibrosis indexes, oxidative stress indexes, and inflammation factors of the DM group increased. Levels of GPT, GOT, AKP, HA, IV-C, PC-Ⅲ, LN, SOD, MAD, NO, and ROS of the 3.0 g/kg therapy group decreased after administration, while levels of GSH-PX and CAT increased. Levels of CRP and IL-6 of three therapy groups decreased significantly and the hepatic fibrosis alleviated. Conclusion Jinlida granules have protective effect on the liver injury of mice with type 1 diabetes mellitus. The mechanism may be relevant to the decrease of oxidative stress reaction and alleviation of inflammation.

Key words: Jinlida granules, diabetes mellitus, liver injury, hepatic fibrosis, oxidative stress； inflammation